alphavirus
belong
togavirida
famili
mainli
arthropodborn
virus
transmit
vector
mosquito
found
wide
throughout
world
except
alphavirus
caus
variou
clinic
manifest
rang
febril
ill
neurolog
infect
old
world
alphavirus
chikungunya
viru
chikv
semliki
forest
viru
sfv
nyong
nyong
viru
onnv
sindbi
viru
sinv
mayaro
viru
mayv
ross
river
viru
rrv
commonli
caus
febril
ill
pain
arthralgia
contrast
enceph
mainli
caus
new
world
alphavirus
venezuelan
equin
enceph
viru
veev
eastern
equin
enceph
viru
eeev
western
equin
enceph
viru
weev
function
alphaviru
particl
compris
singlestrand
positivesens
rna
deliveri
deliveri
system
involv
protein
shell
consist
capsid
protein
cp
glycoprotein
hostderiv
envelop
acquir
viru
bud
cellular
protein
shell
surround
stabil
protect
positivesens
rna
genom
encod
nonstructur
protein
nsp
structur
nsp
ie
aid
product
new
viral
rna
strand
structur
protein
consist
cp
envelop
glycoprotein
residu
polypeptid
ultim
make
part
matur
tabl
illustr
essenti
known
function
alphaviru
given
viru
detail
understand
process
involv
replic
cycl
vital
design
drug
select
inhibit
viral
replic
without
interf
host
cell
function
illustr
figur
replic
cycl
alphaviru
summar
three
main
stage
viru
entri
intracellular
replic
matur
begin
replic
cycl
alphaviru
infect
host
cell
engag
glycoprotein
cell
surfac
receptor
enter
cell
via
clathrinmedi
viruscontain
endosom
matur
acid
environ
develop
within
endocytot
vesicl
destabil
envelop
glycoprotein
result
conform
chang
initi
fusion
viru
late
endosom
membran
lead
empti
nucleocapsid
cytosol
event
nucleocapsid
disassembl
cytosol
encapsid
genom
gain
access
synthet
machineri
cell
intracellular
replic
proce
alphavirus
use
cellular
machineri
translat
viral
polyprotein
fulllength
genom
polyprotein
process
stepwis
individu
nsp
proteolyt
cleavag
event
earli
process
produc
associ
form
primari
replic
complex
rc
perform
negativesens
rna
synthesi
event
process
produc
individu
nsp
associ
form
matur
rc
event
matur
rc
regul
synthesi
positivesens
rna
well
transcript
subgenom
mrna
use
negativesens
rna
templat
event
simultan
structur
precursor
also
translat
subgenom
matur
stage
cp
first
cleav
structur
polyprotein
polyprotein
assembl
newli
synthes
positivesens
singlestrand
rna
molecul
form
nucleocapsid
event
respect
molecul
transloc
endoplasm
reticulum
posttransl
modif
event
prior
arriv
heterodim
plasma
membran
cleav
furin
golgi
apparatu
activ
infect
postmodifi
envelop
glycoprotein
transloc
plasma
assembl
matur
bud
phase
assembl
virion
exit
host
cell
acquir
hostderiv
lipid
envelop
contain
integr
membran
glycoprotein
event
prior
chikv
consid
rel
less
import
viral
infect
mainli
confin
local
outbreak
asia
chikv
reemerg
caus
larg
outbreak
infect
popul
french
island
la
sever
natur
chikv
transmiss
spread
chikv
acceler
increas
global
wherebi
chikv
introduc
nonendem
region
travel
return
chikvepidem
year
chikv
reemerg
global
pathogen
spread
africa
throughout
indian
ocean
pacif
caus
million
case
almost
although
death
due
chikv
infect
rare
clinic
case
asia
especi
countri
health
servic
procedur
poorli
develop
result
high
recogn
antivir
therapi
treat
alphaviru
infect
current
treatment
ie
administr
nonsteroid
antiinflammatori
drug
nsaid
paracetamol
allevi
symptom
diseas
past
year
report
smallmolecul
alphaviru
inhibitor
develop
potenti
nearli
half
discov
obtain
natur
mani
virusspecif
host
target
involv
viru
replic
target
antivir
therapi
directact
inhibitor
design
act
virusspecif
target
ie
nsp
structur
protein
hosttarget
inhibitor
inhibit
function
hostderiv
protein
activ
involv
alphaviru
replic
figur
illustr
list
directact
hosttarget
inhibitor
mechan
action
disrupt
viru
attach
entri
intracellular
replic
viru
matur
bud
tabl
summar
vitro
antivir
properti
inhibitor
describ
term
ie
concentr
inhibitor
requir
reduct
cell
viabil
ie
concentr
inhibitor
requir
produc
total
antialphavir
effect
unless
state
otherwis
doxycyclin
semisynthet
tetracyclin
antibiot
commonli
use
treat
bacteri
infect
drug
discov
synergist
vitro
antichikv
effect
administ
ribavirin
ie
around
improv
valu
compar
doxycyclin
ribavirin
alon
doxycyclin
inhibit
viru
attach
comput
studi
reveal
doxycyclin
bind
glycoprotein
henc
impair
import
conform
chang
protein
bind
cell
surfac
observ
synergist
effect
doxycyclin
ribavirin
could
due
doxycyclin
target
entri
stage
ribavirin
target
intracellular
replic
stage
arbidol
figur
origin
licens
russia
treatment
influenza
respiratori
viral
timeofaddit
studi
show
arbidol
demonstr
greater
antivir
activ
chikv
treatment
infect
suggest
arbidol
block
earliest
stage
chikv
replic
cycl
ie
viru
attach
andor
viru
entri
relationship
sar
studi
similar
analogu
arbidol
also
analogu
two
arbidol
tertbutyl
ester
deriv
possess
sulphoxid
group
demonstr
similar
activ
arbidol
better
cytotox
profil
figur
sign
resist
observ
cell
infect
mutant
chikv
treat
sinc
posit
mutat
local
domain
interact
cell
receptor
occur
believ
arbidol
deriv
demonstr
antichikv
activ
block
interact
surfac
receptor
chikv
attach
phenothiazin
compound
ie
chlorpromazin
ethopropazin
methdilazin
perphenazin
thiethylphenazin
thioridazin
drug
use
treatment
psychot
allergi
diseas
figur
compound
test
entri
inhibit
assay
employ
heatsensit
sfv
strain
effect
inhibit
sfv
entri
babi
hamster
kidney
bhk
cell
one
phenothiazin
chlorpromazin
report
inhibit
hcv
entri
block
format
clathrinco
pit
plasma
membran
clathrinmedi
endocytosi
viral
henc
believ
inhibit
sfv
entri
like
consequ
misassembl
clathrin
lattic
presenc
phenothiazin
chloroquin
commonli
use
antimalari
drug
extens
investig
viral
infect
drug
demonstr
signific
vitro
inhibit
sfv
sinv
chikv
antivir
action
chloroquin
involv
inhibit
viru
entri
increas
endosom
ph
critic
valu
need
lowphdepend
fusion
reaction
occur
henc
prevent
fusion
protein
transfer
viru
nucleocapsid
howev
chloroquin
effect
administ
mice
infect
sfv
instead
drug
enhanc
sfv
replic
vivo
aggrav
addit
result
doubleblind
placebocontrol
random
trial
chikvinfect
patient
yield
convinc
data
obatoclax
anticanc
drug
antagonist
prosurviv
protein
trigger
apoptosi
cancer
cell
drug
screen
alphaviru
infect
ie
sinv
sfv
chikv
demonstr
antialphavir
activ
submicromolar
timeofaddit
entri
inhibit
assay
show
drug
inhibitori
activ
sfv
mechanist
drug
neutral
acid
environ
late
endosom
henc
inhibit
viru
addit
resist
studi
round
passag
sfv
presenc
obatoclax
obtain
partial
resist
mutant
mutat
amino
residu
ie
found
membran
fusion
among
triazolo
one
evalu
screen
programm
chikv
infect
vitro
lead
compound
triazolo
one
figur
identifi
found
possess
antivir
activ
variou
chikv
strain
interestingli
smallmolecul
inhibitor
select
toward
inhibit
chikv
replic
relat
virus
sinv
delang
et
discov
compound
demonstr
inhibit
chikv
replic
postentri
step
viral
protein
translat
viral
rna
synthesi
sinc
could
obtain
enzymat
activ
chikv
investig
mechan
veev
result
show
inhibit
activ
veev
specif
vitro
guanylyltransferas
gt
activ
henc
caus
signific
inhibit
veev
addit
chikv
mutant
possess
substitut
also
found
highli
resist
antivir
effect
compound
sadenosyl
methionin
adomet
sadenosyl
homocystein
adohci
natur
substrat
alphaviru
mrna
cap
machineri
analogu
adomet
adohci
sinefungin
shown
potent
inhibitor
rna
cap
sinefungin
evalu
methyltransferas
mt
gt
activ
veev
enzymat
assay
demonstr
reason
good
activ
mt
demonstr
studi
sinefungin
like
function
two
level
ie
inhibit
methyltransf
compet
methyl
donor
adomet
block
activ
adohci
gt
past
decad
smallmolecul
inhibitor
chikv
replic
inhibitori
effect
report
thiazolidinon
ie
compound
figur
demonstr
antivir
activ
chikv
limit
cytotox
liabil
activ
molecular
dock
studi
reveal
inhibitor
establish
crucial
hydrophob
interact
pocket
chikv
hydrogen
bond
interact
key
residu
suggest
thiazolidinon
deriv
could
inhibitor
chikv
anoth
strategi
smallmolecul
drug
discoveri
virtual
screen
method
util
homolog
model
chikv
base
veev
proteas
templat
creat
screen
commerci
avail
librari
million
compound
bind
activ
proteas
activ
site
compound
figur
possess
hydrazid
structur
demonstr
signific
inhibit
viru
yield
chikvinduc
cytopath
effect
cpe
reduct
use
hydrazid
lead
sar
approach
adopt
design
evalu
seri
hydrazid
compound
replac
cyclopropan
ring
hydrazid
alken
moieti
result
hydrazid
figur
demonstr
slightli
improv
antivir
new
class
hydrazidebas
inhibitor
also
design
gener
employ
comput
pharmacophor
replac
use
hydrazid
hydrazid
figur
show
inhibit
cleavag
peptid
substrat
chikv
fluoresc
reson
energi
transfer
fret
base
cellfre
proteas
assay
also
demonstr
antichikv
activ
low
micromolar
interestingli
reduct
viral
rna
synthesi
infecti
viru
product
observ
cell
pretreat
hydrazid
suggest
could
mode
action
associ
move
forward
would
interest
analys
inhibitori
properti
individu
cistran
isom
hydrazid
stereochemistri
could
major
determin
compound
activ
peptidomimet
strategi
also
employ
design
smallmolecul
inhibitor
chikv
peptidomimet
inhibitor
modifi
specif
amino
acid
sequenc
aggi
natur
substrat
chikv
studi
led
identif
peptidomimet
figur
demonstr
maximum
inhibit
chikv
replic
molecular
model
reveal
peptidomimet
bind
chikv
via
coval
interact
unsatur
keton
function
catalyt
residu
quinazolinon
compound
figur
demonstr
potent
vitro
activ
variou
veev
strain
weev
well
good
vivo
antivir
mutat
two
key
residu
ntermin
region
drug
resist
studi
indic
site
action
could
viral
util
start
point
classic
optim
studi
due
preliminari
promis
antiveev
activ
good
physiochem
profil
studi
amidin
figur
identifi
possess
nearli
improv
antivir
potenc
best
quinazolinonebas
analogu
good
vivo
mechanist
studi
use
mutant
veev
carri
mutat
show
possibl
target
critic
function
veev
rc
henc
inhibit
viral
involv
viral
rna
synthesi
cofactor
rc
also
virul
factor
block
cellular
gene
transcript
ie
transcript
shutoff
induc
degrad
catalyt
subunit
rna
polymeras
employ
highthroughput
phenotyp
function
assay
identifi
small
molecul
target
transcript
shutoff
natur
product
deriv
figur
partial
block
activ
inhibit
chikv
replic
vitro
identifi
screen
chemic
librari
favipiravir
analogu
pyrazin
figur
report
broadspectrum
antivir
activ
variou
rna
virus
includ
weev
favipiravir
demonstr
potent
vitro
vivo
activ
chikv
weev
also
demonstr
inhibitori
activ
chikv
rna
synthesi
uridin
label
phenotyp
resist
favipiravir
also
observ
cell
infect
mutant
chikv
genotyp
mutat
chikv
suggest
favipiravir
possibl
inhibit
chikv
replic
via
interfer
rnadepend
rna
polymeras
rdrp
molecular
hybrid
benzimidazol
mbzmnibt
figur
develop
investig
vitro
chikv
hybrid
compound
reduc
viral
protein
rna
product
concentr
also
inhibit
chikv
infect
earli
late
phase
replic
indic
multipl
mechan
antichikv
addit
molecular
dock
studi
reveal
favour
bind
affin
mbzmnibt
homolog
model
chikv
class
natur
product
ie
secopregnan
steroid
glaucogenin
c
monosugarglycosid
cynatratosid
strobilanth
cusia
three
new
pentasugar
glycosid
glaucogenin
c
cyananchum
paniculatum
found
possess
effect
inhibit
alphavirus
sinv
eeev
nanomolar
steroidcontain
compound
includ
secopregnan
steroid
glycosid
figur
suppress
express
sinv
subgenom
rna
sgrna
predominantli
without
affect
accumul
viral
genom
studi
mode
action
compound
may
involv
alter
structur
sgrna
promot
therebi
affect
bind
transcript
complex
sgrna
promot
result
decreas
express
dioxan
discov
suitabl
ligand
bound
nice
hydrophob
pocket
sinv
cp
protein
crystal
employ
crystal
structur
hydrophob
pocket
molecular
dock
studi
seri
dioxanebas
antivir
predict
bind
hydrophob
pocket
synthes
evalu
sinv
although
potent
dioxanebas
compound
figur
demonstr
inhibit
sinv
replic
demonstr
inhibit
nucleocapsid
assembl
cp
assembl
picolin
acid
pca
figur
previous
report
antivir
properti
hiv
human
herp
simplex
molecular
dock
studi
pca
show
stronger
bind
affin
conserv
hydrophob
pocket
homologymodel
chikv
cp
compar
pca
also
show
strong
bind
affin
purifi
chikv
cp
isotherm
titrat
calorimetri
surfac
plasmon
reson
fluoresc
spectroscopi
pca
nontox
mm
demonstr
antichikv
activ
caus
signific
inhibit
viral
rna
product
plaqu
format
mm
take
find
togeth
pca
may
inhibit
chikv
matur
via
interf
cp
format
suramin
symmetr
sulphon
naphthylurea
compound
first
use
antiparasit
agent
treatment
african
trypanosomiasi
sinc
research
suramin
gain
momentum
anticanc
antivir
potenti
discov
antivir
activ
chikv
sfv
sinv
recent
suramin
restrict
chikv
multipl
via
inhibit
chikv
rna
furthermor
variou
studi
also
demonstr
suramin
interfer
postattach
stage
chikv
replic
cycl
ie
viru
entri
fusion
step
sar
studi
suramin
show
remov
moieti
suramin
result
loss
activ
drop
molecular
dock
studi
show
suramin
dock
caviti
chikv
domain
ii
domain
c
interact
may
inhibit
process
viru
releas
result
reduc
treatment
suramin
shown
reduc
viral
load
well
reduc
foot
swell
inflamm
cartilag
damag
chikvinfect
clinic
efficaci
suramin
amelior
chikvinduc
arthriti
patient
would
worth
explor
near
futur
figur
unbranch
nonylsubstitut
serotonin
shown
possess
affin
serotonin
antivir
evalu
studi
vitro
reoviru
infect
imped
viru
entri
delay
intracellular
transport
incom
virion
affect
distribut
earli
endosom
therebi
lead
inhibit
viru
exhibit
potent
antichikv
strongli
suggest
serotonin
receptor
signal
could
one
crucial
regulatori
factor
involv
entri
virus
divers
famili
includ
chikv
synthet
flavaglin
ie
sulfonyl
amidin
known
bind
host
cellular
receptor
prohibitin
phb
number
differ
pathogen
includ
chikv
dengu
viru
denv
hiv
use
entri
host
compound
figur
assess
antivir
evalu
chikv
product
phbexpress
cell
significantli
reduc
chikv
addit
coloc
studi
phb
chikv
presenc
compound
show
interfer
chikv
nucleosid
analogu
contain
sugar
ribos
deoxyribos
far
import
class
antivir
ribavirin
figur
one
first
antialphavir
inhibitor
report
show
reduc
sfvinduc
cpe
chick
embryo
compound
consid
treatment
alphavir
infect
studi
show
combin
ribavirin
subsynergist
antivir
effect
chikv
sfv
number
mechan
associ
ribavirin
propos
predomin
mechan
action
inhibit
dehydrogenas
impdh
lead
deplet
cellular
gtp
pool
need
viru
deriv
ribavirin
figur
also
describ
inhibit
sfv
anoth
nucleosid
analogu
figur
broadspectrum
antimetabolit
inhibit
dna
rna
viru
replic
chikv
replac
adenin
guanin
core
nucleosid
result
figur
show
antivir
activ
carbocyl
analogu
cytidin
carbodin
figur
shown
deplet
ctp
pool
inhibit
ctp
synthetas
convert
utp
ctp
therebi
inhibit
rna
synthesi
replic
cycl
rang
dna
rna
two
enantiomer
pure
carbodin
compound
carbodin
carbodin
screen
veevinduc
interestingli
carbodin
exhibit
activ
wherea
carbodin
demonstr
potent
vitro
vivo
antivir
cordycepin
figur
known
influenc
replic
sever
virus
via
reduc
poli
content
viral
howev
antivir
studi
sfv
infect
demonstr
cordycepin
specif
inhibit
synthesi
poli
sequenc
instead
inhibit
synthesi
viru
mycophenol
acid
figur
weak
organ
acid
wellknown
immunosuppress
agent
first
isol
fungu
penicillium
stoloniferum
demonstr
broadspectrum
antivir
activ
replic
sever
virus
includ
similar
ribavirin
mechan
action
mycophenol
acid
vitro
base
inhibit
cellular
impdh
brefeldin
macrolid
lacton
antibiot
produc
fungu
eupenicillium
brefeldianum
inhibit
sinv
protein
synthesi
rna
replic
possibl
due
interfer
format
vesicl
requir
viral
rna
harringtonin
figur
cephalotaxin
ester
deriv
japanes
plum
yew
cephalotaxu
harringtonia
known
inhibitor
eukaryot
protein
demonstr
dosedepend
inhibit
chikv
earli
event
chikv
replic
viru
entri
significantli
reduc
chikv
rna
synthesi
protein
noncytotox
concentr
mechan
action
harringtonin
suggest
specif
chikv
instead
exercis
inhibit
eukaryot
larg
ribosom
unit
therebi
suppress
viral
protein
translat
lead
decreas
level
rc
viral
lanatosid
c
approv
cardiac
glycosid
act
inhibit
nakatpas
ion
pump
demonstr
potent
inhibitori
activ
variou
rna
virus
denv
chikv
optimum
level
intracellular
na
k
cytosol
environ
import
proper
replic
variou
dna
rna
virus
increas
level
intracellular
na
reduc
intracellular
k
caus
lanatosid
c
affect
replic
chikv
similarli
anoth
inhibitor
nakatpas
ion
pump
digoxin
figur
show
enhanc
inhibit
chikv
extracellular
na
introduc
exhibit
margin
inhibit
chikv
extracellular
k
digoxin
display
broadspectrum
inhibitori
effect
alphavirus
rrv
addit
mutat
valin
residu
isoleucin
observ
digoxinresist
chikv
popul
suggest
digoxin
could
inhibit
chikv
replic
disrupt
rna
although
digoxin
known
cytotox
owe
narrow
therapeut
index
treat
heart
observ
vitro
chikv
inhibit
digoxin
due
cytotox
ie
toxic
occur
dose
time
antivir
activ
preclin
studi
use
vivo
mous
model
might
employ
verifi
margin
toxic
antivir
efficaci
improv
poor
vitro
metabol
properti
report
inhibitor
weev
thieno
pyrrol
figur
class
indol
compound
ie
bioisoster
thieno
pyrrol
evalu
activ
weev
investig
led
discoveri
indol
analogu
r
enantiom
figur
possess
better
metabol
stabil
mous
liver
microsom
mlm
compar
halflif
versu
min
also
potent
antivir
activ
good
cytotox
profil
vivo
subsequ
sar
studi
variou
structur
modif
vari
substitu
posit
indol
core
well
scaffold
hop
ie
replac
indol
pyrrol
benzimidazol
imidazol
investig
led
discoveri
termin
pyridinyl
group
figur
exhibit
improv
potenc
compar
weev
replicon
mechanist
class
thieno
pyrrol
indol
compound
ie
directli
inhibit
weev
rdrp
viral
enzymat
activ
instead
possibl
target
host
factor
modul
cellular
capdepend
translat
pathway
eukaryot
initi
factor
signal
continu
effort
improv
physiochem
properti
contribut
vivo
barrier
bbb
permeabl
indol
indol
core
replac
lower
molecular
weight
core
structur
pyrrol
simpl
phenyl
effort
two
anthranilamid
analogu
figur
discov
possess
better
metabol
stabil
mlm
halflif
versu
min
improv
aqueou
solubl
nearli
equival
passiv
permeabl
measur
artifici
membran
permeabl
assay
without
lose
antiweev
earlier
report
show
alphaviru
matur
envelop
glycoprotein
precursor
usual
cleav
short
multibas
motif
furin
furinlik
inhibit
matur
chikv
virion
synthet
peptid
mimic
conserv
sequenc
kr
x
kr
cleavag
site
chikv
name
decanoylrvrkchloromethyl
keton
fi
screen
antichikv
activ
peptidomimet
behav
like
furin
inhibitor
induc
inhibit
chikv
infect
prevent
process
interestingli
fi
also
show
inhibit
chikv
entri
use
pretreat
suggest
could
mode
action
associ
deubiquintinas
dub
class
cystein
proteas
involv
proteasom
degrad
regul
cellular
process
unfold
protein
studi
show
mani
virus
depend
ubiquitin
ub
cycl
hijack
cellular
ubmodifi
enzym
includ
dub
assist
postentri
investig
relationship
dub
viru
infect
inhibitor
dub
figur
evalu
determin
whether
dub
promot
noroviru
result
show
inhibit
proteasomeassoci
dub
known
restrict
replic
sever
rna
virus
includ
sinv
decay
viral
protein
activ
upon
inhibit
deriv
possess
fluorosubstitut
substitut
pyridinyl
group
solubil
group
phenyl
group
explor
improv
aqueou
solubl
deriv
figur
significantli
reduc
viru
titr
sinvinfect
vero
mitogenactiv
protein
map
signal
pathway
suggest
activ
virus
potenti
confer
prosurviv
statu
infect
cell
order
product
infect
cycl
gener
suffici
progeni
reason
inhibitor
map
kinas
extracellular
signalregul
kinas
erk
figur
evalu
found
possess
inhibitori
activ
veev
replic
nontox
concentr
rang
earli
late
event
viru
replic
anoth
natur
product
berberin
figur
also
found
imped
alphaviru
replic
inhibit
phosphoryl
erk
therebi
affect
egress
progeni
virion
sinc
affect
viru
entri
enzymat
activ
viral
vivo
antivir
efficaci
studi
berberin
reveal
could
behav
antivir
agent
ie
reduc
viral
load
infect
mice
antiinflammatori
agent
ie
decreas
joint
swell
infect
mice
interestingli
berberin
demonstr
broadspectrum
antivir
activ
old
world
alphavirus
sinv
demonstr
broadspectrum
antivir
activ
new
world
alphavirus
eeev
hand
kinas
inhibitor
librari
contain
compound
screen
vitro
chikv
infect
among
primari
hit
compound
contain
benzofuran
thiazol
pyrrolopyridin
core
structur
identifi
benzofuran
pyrrolopyridin
figur
exhibit
signific
reduct
viru
titr
activ
dopamin
receptor
gener
seri
downstream
signal
phosphoryl
erk
occur
turn
regul
viral
replic
replic
cycl
rang
dna
rna
treatment
antagonist
dopamin
receptor
contain
dihydrodibenzothiepin
scaffold
figur
denvinfect
cell
inhibit
phosphoryl
erk
result
inhibit
viru
replic
especi
earli
stage
replic
cycl
addit
inhibit
replic
sinv
suggest
dopamin
receptor
signal
could
one
regulatori
factor
involv
replic
alphaviru
degrad
target
mrna
argonaut
ago
protein
microrna
mirna
along
cofactor
becom
incorpor
rnainduc
silenc
complex
risc
turn
associ
target
associ
cellular
mirna
mirna
process
machineri
veev
replic
shown
mark
decreas
veev
replic
observ
absenc
acriflavin
acf
figur
mixtur
trypaflavin
found
inhibit
associ
cofactor
assist
rna
load
onto
risc
therebi
reduc
veev
interestingli
acf
demonstr
broadspectrum
antivir
activ
weev
eeev
suggest
could
act
upon
pathway
conserv
among
encephalit
howev
acf
treatment
infect
balbc
mice
significantli
reduc
viru
could
due
short
biolog
halflif
account
differ
vivo
vitro
effect
veev
assist
proper
fold
viral
protein
stabil
protein
heat
stress
play
import
role
replic
mani
dna
rna
involv
chikv
rc
interact
facilit
viru
reason
inhibitor
geldanamycin
figur
investig
found
inhibit
chikv
veev
cp
known
associ
cellular
protein
host
traffick
protein
ie
cellular
importin
chromosom
mainten
nuclear
pore
complex
uniqu
abil
block
nuclear
import
transcript
factor
requir
antivir
respons
export
newli
synthes
cellular
henc
host
traffick
protein
viabl
target
antivir
design
specif
interrupt
interact
cp
protein
nuclear
transport
inhibitor
mifepriston
ivermectin
leptomycin
b
shown
inhibit
veev
replic
alter
veev
cp
local
leptomycin
b
welldocu
inhibitor
streptomyc
metabolit
potent
restrict
cp
nucleu
make
unavail
cytoplasm
form
viabl
sinc
leptomycin
b
rather
cytotox
need
investig
new
gener
inhibitor
henc
seri
select
inhibitor
nuclear
export
sine
compound
figur
analogu
selinexor
compound
confin
veev
cp
nucleu
lead
deplet
amount
cytoplasm
cp
ie
intracellular
cp
releas
cp
ie
extracellular
cp
demonstr
western
blot
lead
decreas
viru
assembl
andor
releas
matur
virion
serial
passag
veevinfect
cell
presenc
result
mutat
within
nuclear
local
nuclear
export
signal
cp
ie
confirm
sine
compound
exert
antivir
activ
target
cp
bortezomib
figur
dipeptidyl
boron
acid
specif
revers
inhibit
ubiquitin
result
earli
stage
veev
infecti
cycl
affect
bortezomib
fusion
stage
veev
cp
ubiquitin
proteasom
degrad
releas
viral
bortezomib
treatment
also
decreas
multipl
virul
new
world
number
report
directact
hosttarget
inhibitor
alphavirus
highlight
emphasi
mechan
action
includ
drug
alreadi
market
current
use
treatment
diseas
doxycyclin
phenothiazin
chloroquin
obatoclax
suramin
digoxin
discov
drug
repurpos
screen
challeng
improv
potenc
compound
chikv
retain
good
druglik
properti
inhibitori
activ
test
compound
alphaviru
rang
strong
weak
inhibit
depend
type
assay
use
secopregnan
steroid
glycosid
strongest
inhibitor
nm
sinv
replic
eeevinduc
cpe
respect
suramin
display
weakest
activ
sinvinduc
cpe
despit
select
antivir
activ
directact
inhibitor
favipiravir
function
alphaviru
element
compar
host
cellular
target
use
directact
inhibitor
treatment
regimen
lead
rapid
select
resist
virus
hand
hosttarget
inhibitor
digoxin
bortezomib
berberin
sine
compound
repres
altern
approach
may
increas
barrier
resist
achiev
broadspectrum
antivir
coverag
rang
alphavirus
howev
possibl
downsid
potenti
ontarget
toxic
exemplifi
digoxin
inhibitor
ion
pump
show
toxic
concentr
low
besid
develop
smallmolecul
inhibitor
therapi
alphavirus
form
unconvent
antivir
therapi
rna
interfer
rnai
base
therapi
antivir
immunotherapi
consid
given
abil
specif
silenc
gene
interest
viral
rna
therebi
prevent
viral
protein
translat
short
interf
rna
sirna
mirna
constitut
rnaibas
therapi
offer
sever
advantag
convent
drug
potenti
therapeut
agent
overcom
patient
complianc
drug
toxic
innat
immun
system
play
central
role
progress
control
alphaviru
infect
smallmolecul
immunomodul
acid
stimul
express
antivir
protein
also
explor
potenti
therapeut
agent
alphaviru
recent
advanc
rnai
technolog
develop
character
receptor
pathway
innat
immun
system
associ
alphaviru
infect
possibl
develop
highli
target
rnaibas
immunomodulatori
therapi
treatment
alphaviru
infect
